INDV — Indivior Pharmaceuticals, Share Price
0.000.00%
Last trade - 00:00- $4.53bn
- $4.66bn
- $1.24bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.41 | ||
| PEG Ratio (f) | 0.37 | ||
| EPS Growth (f) | 39.84% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.66 | ||
| EV to EBITDA | 17.12 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 91.29% | ||
| Return on Equity | n/a | ||
| Operating Margin | 21.15% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 791 | 901 | 1,093 | 1,188 | 1,239 | 1,239.84 | 1,292.8 | 13.88% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +67.67 | -31.14 | +37.56 | -20.01 | +64.61 | +74.21 | +8.85 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Directors
- Graham Hetherington NEC (58)
- Mark Crossley CEO
- Ryan Preblick CFO
- Jon Fogle CHO
- Christian Heidbreder CSO
- Cynthia Cetani CCO
- Murali Gopal OTH
- Richard Simkin OTH
- Jon Wasserman OTH
- Hillel West OTH
- Kathryn Hudson SEC
- Jerome Lande NED (45)
- Peter Bains NID (64)
- Joanna Le Couilliard NID
- A. Thomas McLellan NID
- Lorna Parker NID
- Daniel Phelan NID (71)
- Mark Stejbach NID (58)
- Juliet Thompson NID
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- October 28th, 2025
- Public Since
- June 12th, 2023
- No. of Shareholders
- 139
- No. of Employees
- 827
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 121,000,000
- Address
- 10710 Midlothian Turnpike, DOVER, 23235
- Web
- https://www.indivior.com/
- Phone
- +1 8043791090
- Contact
- Jason Thompson
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for INDV
Indivior Pharmaceuticals, Inc at Goldman Sachs Healthcare Conference
Half Year 2026 Indivior Pharmaceuticals, Inc Earnings Release
Q3 2026 Indivior Pharmaceuticals, Inc Earnings Release
Similar to INDV
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals,
NASDAQ Global Select Market
Arcutis Biotherapeutics
NASDAQ Global Select Market
FAQ
What is the Indivior Pharmaceuticals, share price?
As of Today at 03:18 UTC, shares in Indivior Pharmaceuticals, are trading at $37.46. This share price information is delayed by 15 minutes.
How has the Indivior Pharmaceuticals, share price performed this year?
Shares in Indivior Pharmaceuticals, last closed at $37.46 and the price had moved by +231.8% over the past 365 days. In terms of relative price strength the Indivior Pharmaceuticals, share price has outperformed the S&P500 Index by +160.33% over the past year.
What are the analyst and broker recommendations for Indivior Pharmaceuticals,?
The overall consensus recommendation for Indivior Pharmaceuticals, is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Indivior Pharmaceuticals, dividend yield?
Indivior Pharmaceuticals, does not currently pay a dividend.
Does Indivior Pharmaceuticals, pay a dividend?
Indivior Pharmaceuticals, does not currently pay a dividend.
When does Indivior Pharmaceuticals, next pay dividends?
Indivior Pharmaceuticals, does not currently pay a dividend.
How do I buy Indivior Pharmaceuticals, shares?
To buy shares in Indivior Pharmaceuticals, you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Indivior Pharmaceuticals,?
As of the previous close price of $37.46, shares in Indivior Pharmaceuticals, had a market capitalisation of $4.53bn.
Where are Indivior Pharmaceuticals, shares listed?
Here are the trading details for Indivior Pharmaceuticals,:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: INDV
What kind of share is Indivior Pharmaceuticals,?
Based on an overall assessment of its quality, value and momentum Indivior Pharmaceuticals, is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Indivior Pharmaceuticals, share price forecast for 2026?
The analyst consensus target price for shares in Indivior Pharmaceuticals, is $49.83. That is 33.02% above the last closing price of $37.46.
Analysts covering Indivior Pharmaceuticals, currently have a consensus Earnings Per Share (EPS) forecast of $3.48 for the next financial year.
Find out moreWhat is the trend in the Indivior Pharmaceuticals, share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Indivior Pharmaceuticals,. Over the past six months, its share price has outperformed the S&P500 Index by +3%.
As of the last closing price of $37.46, shares in Indivior Pharmaceuticals, were trading +21.92% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Indivior Pharmaceuticals, PE Ratio?
The Indivior Pharmaceuticals, PE ratio based on its reported earnings over the past 12 months is 10.41. The shares last closed at $37.46.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Indivior Pharmaceuticals,?
Indivior Pharmaceuticals,'s management team is headed by:
- Graham Hetherington - NEC
- Mark Crossley - CEO
- Ryan Preblick - CFO
- Jon Fogle - CHO
- Christian Heidbreder - CSO
- Cynthia Cetani - CCO
- Murali Gopal - OTH
- Richard Simkin - OTH
- Jon Wasserman - OTH
- Hillel West - OTH
- Kathryn Hudson - SEC
- Jerome Lande - NED
- Peter Bains - NID
- Joanna Le Couilliard - NID
- A. Thomas McLellan - NID
- Lorna Parker - NID
- Daniel Phelan - NID
- Mark Stejbach - NID
- Juliet Thompson - NID